Heat Biologics Inc. (NASDAQ:HTBX) went down by -1.63% from its latest closing price compared to the recent 1-year high of $4.30. The company’s stock price has collected -5.47% of loss in the last five trading sessions. Press Release reported on 09/17/20 that Thinking about buying stock in General Electric, Heat Biologics, Vaccinex Inc, Nikola Corp, or Plug Power?
Is It Worth Investing in Heat Biologics Inc. (NASDAQ :HTBX) Right Now?
Plus, the 36-month beta value for HTBX is at 0.55. Opinions of the stock are interesting as 3 analysts out of 3 who provided ratings for Heat Biologics Inc. declared the stock was a “buy,” while 0 rated the stock as “overweight,” 0 rated it as “hold,” and 0 as “sell.”
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free.
The average price from analysts is $4.63. HTBX currently public float of 143.73M and currently shorts hold a 4.96% ratio of that float. Today, the average trading volume of HTBX was 32.10M shares.
HTBX’s Market Performance
HTBX stocks went down by -5.47% for the week, with a monthly drop of -2.42% and a quarterly performance of 43.21%, while its annual performance rate touched 157.45%. The volatility ratio for the week stands at 5.08% while the volatility levels for the past 30 days are set at 11.49% for Heat Biologics Inc.. The simple moving average for the period of the last 20 days is -1.81% for HTBX stocks with a simple moving average of 36.12% for the last 200 days.
Analysts’ Opinion of HTBX
Noble Financial, on the other hand, stated in their research note that they expect to see HTBX reach a price target of $16. The rating they have provided for HTBX stocks is “Buy” according to the report published on January 08th, 2016.
H.C. Wainwright gave a rating of “Buy” to HTBX, setting the target price at $13 in the report published on May 26th of the previous year.
HTBX Trading at -22.90% from the 50-Day Moving Average
After a stumble in the market that brought HTBX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -71.86% of loss for the given period.
Volatility was left at 11.49%, however, over the last 30 days, the volatility rate increased by 5.08%, as shares surge +9.01% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -55.84% lower at present.
During the last 5 trading sessions, HTBX fell by -5.47%, which changed the moving average for the period of 200-days by +163.04% in comparison to the 20-day moving average, which settled at $1.2372. In addition, Heat Biologics Inc. saw 154.74% in overturn over a single year, with a tendency to cut further gains.
Stock Fundamentals for HTBX
Current profitability levels for the company are sitting at:
- -636.11 for the present operating margin
The net margin for Heat Biologics Inc. stands at -656.51. The total capital return value is set at -85.58, while invested capital returns managed to touch -87.94. Equity return is now at value -77.30, with -55.40 for asset returns.
Based on Heat Biologics Inc. (HTBX), the company’s capital structure generated 14.21 points at debt to equity in total, while total debt to capital is 12.44. Total debt to assets is 3.58, with long-term debt to equity ratio resting at 12.25. Finally, the long-term debt to capital ratio is 10.72.
When we switch over and look at the enterrpise to sales, we see a ratio of 0.84, with the company’s debt to enterprise value settled at 0.75. The receivables turnover for the company is 96.00 and the total asset turnover is 0.05. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.80.